MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/eurheartj/ehae923

Медицинская библиотека · European heart journal · 2025

Tafamidis in octogenarians with wild-type transthyretin cardiac amyloidosis: an international cohort study.

Debonnaire Philippe, Dujardin Karl, Verheyen Nicolas, Pouleur Anne-Catherine, Droogmans Steven, Claeys Mathias, Bohyn Alexandre, Bogaerts Kris, El Haddad Milad, Christiaen Emma, Wyseure Nicolas, Zach David K, Buytaert Lars, Jacobs Annemie, Buysschaert Ian, Trenson Sander, Van Hoeyweghen Raf, Tavernier René

СтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND AND AIMS: In real-world, wild-type transthyretin cardiomyopathy is increasingly diagnosed in patients ≥ 80 years old (octogenarians), although being underrepresented in randomized clinical trials. Specific data on natural course and outcome under tafamidis treatment in octogenarians are therefore scarce. The impact of tafamidis treatment on mortality in real-world wild-type transthyretin cardiomyopathy octogenarians was studied.

METHODS

An international, multicentre cohort study of 710 consecutive wild-type transthyretin cardiomyopathy patients with mean follow-up of 2.2 ± 1.8 years for all-cause mortality endpoint was performed.

RESULTS

The cohort consisted of 58.5% (415/710) octogenarians (85 ± 4 years, 74.2% male). Before tafamidis availability, natural course in octogenarians (148/257) vs. non-octogenarians (109/257) was poor, with 16% 1-year and 71% 5-year mortality vs. 8% and 47%, respectively (P < .001). Since tafamidis availability, 70.1% (253/361) octogenarians were initiated on tafamidis vs. 83.7% (231/276) non-octogenarians (P < .001). Tafamidis discontinuation was similar (octogenarians 10.3% and non-octogenarians 7.4%; P = .260). Overall tafamidis treated vs. untreated octogenarians had better unadjusted survival (P < .001), with 5% 1-year and 24% 3-year mortality. Tafamidis treatment associated with lower mortality after propensity score matching on baseline variables, including age, National Amyloidosis Centre stage, and New York Heart Association class in on average 394 subjects [hazard ratio (HR) = 0.53, 95% confidence interval (CI) 0.34-0.84, P = .007], also in octogenarians (HR = 0.57, 95% CI 0.33-1.01, P = .053). Neither age at diagnosis (P = .217) nor at treatment initiation (P = .154) interacted with tafamidis mortality benefit. Octogenarians had poorer survival despite tafamidis, when initiated at ≥90 years (HR = 3.3, 95% CI 1.10-9.53, P = .033) and National Amyloidosis Centre Stage ≥3 (HR = 2.4, 95% CI 0.87-6.46, P = .090).

CONCLUSIONS

Real-world tafamidis treatment improves survival without age affecting treatment efficacy, although mortality remains considerable in octogenarians.

Для цитирования: Debonnaire Philippe, Dujardin Karl, Verheyen Nicolas, Pouleur Anne-Catherine, Droogmans Steven, Claeys Mathias, Bohyn Alexandre, Bogaerts Kris, El Haddad Milad, Christiaen Emma, Wyseure Nicolas, Zach David K, Buytaert Lars, Jacobs Annemie, Buysschaert Ian, Trenson Sander, Van Hoeyweghen Raf, Tavernier René. Tafamidis in octogenarians with wild-type transthyretin cardiac amyloidosis: an international cohort study.. European heart journal. 2025. DOI: 10.1093/eurheartj/ehae923.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.